Newly diagnosed multiple myeloma patients unable to undergo stem cell transplants lived significantly longer without their disease progressing when given continuous treatment with…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
As UT Southwestern and Celgene Corporation join efforts to launch a new clinical trial to evaluate a chimeric antigen receptor T-cell therapy,…
The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF), a private organization funding collaborative translational science, recently launched the Adelson Program in…
A combination treatment including Pomalyst (pomalidomide) significantly extended the time until disease progression or death in patients with relapsed or refractory multiple myeloma who were…
PT-112, an investigational small molecule that promotes cancer cell death, has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) for…
Some 68 percent of Canadians would feel helpless if they or someone close to them received a blood cancer diagnosis, found a recent poll commissioned…
